VIR

Vir Biotechnology, Inc. (NASDAQ:VIR) is a commercial-stage immunology company founded in 2016 and headquartered in San Francisco, California. The company went public in October 2019 and focuses on developing therapeutic products to treat and prevent serious infectious diseases. Vir gained significant attention during the COVID-19 pandemic with its SARS-CoV-2 neutralizing antibody Sotrovimab (marketed as Xevudy), which generated substantial revenue in 2022. However, the company has since pivoted away from COVID-19 treatments and is now primarily focused on developing treatments for hepatitis B and hepatitis delta viruses, while also expanding into oncology through T-cell engager therapies acquired from Sanofi in 2024.